ANALYSIS OF ANTIGENICITY OF MUC-1 MUCIN AS A TUMOR ANTIGEN AND POSSIBILITY OF THIS MOLECULE FOR THE USE OF COMBINED ANTI-CANCER IMMUNOTHERAPY WITH GENE TRANSFER by 井上 修平 et al.
「MUC-1分子の腫瘍抗原性の解析と遺伝子導入併用
養子免疫抗癌治療への応用」に関する研究
著者 井上 修平, 加藤 弘文, 岡田 慶夫
発行年 1998-03
その他の言語のタイ
トル
ANALYSIS OF ANTIGENICITY OF MUC-1 MUCIN AS A
TUMOR ANTIGEN AND POSSIBILITY OF THIS MOLECULE
FOR THE USE OF COMBINED ANTI-CANCER
IMMUNOTHERAPY WITH GENE TRANSFER
URL http://hdl.handle.net/10422/6588
ANALYSIS OF ANTIGENICITY OF MUC・1MUCIN AS A TUMOR ANTIGEN 
AND POSSIBILlTY OF THIS MOLECULE FOR THE USE OF COMBINED 
ANTI・CANCERIMMUNOTHERAPY WITH GENE TRANSFER 
(08671356 ) 
Abstracts of Research Project， Grant-in-Aid for Scientific Research (C) (2) 
1996-1997 
接結科大学記J;二J3鐘
ら 一一一一 一一一一一ー すプ}← ， 
Shuhei Inoue 
Second Depar!ment of Surgery 
Shiga U n iversity of Medical Science 
111111111111111111111111 
PREFACE 
CONTRIBUTORS 
Head Investigator 
Shuhei Inoue， Associated Professor， Second Department of Surgery， 
Shiga U n iversity of Medical Science 
I nvestig ators 
Yoshio Okada， Principal， Shiga University of Medical Science 
H irofum i Kato， Associated Professor， Second Department of Surgery， 
Shiga U niversity of Medical Science 
EXPENDITURE 
1996: 
1997: 
Total: 
REFERENCES 
1，200，000 yen 
1，100，000 yen 
2，300，000 yen 
S. Sawai， K.Kontani， J.Hanaoka， M. Ichinose， N.Tezuka， T.Konishi， S.Inoue， 
S. Fujino. Induction of MUC-1 S pecific CTL from P8MC Using Synthetic 
Peptides. 14th Asia P as ific Cancer Conference， 11/1 6・18/1997
K. Kontani， J.Hanaoka， S.Sawai， M.Ichinose， N. Tezuka， T.Konishi， S.Inoue， 
S. Fujino. Involvement of Granzyme 8 and Perforine contained in cytotoxic 
granules in suppression of cancer cells metastasizing to regional nodes in 
patientswith breastandlungcancers. 14th Asia .Pasific Cancer 
Conference ，11/1 6・18/1997
K. Kontani S. Sawai， N.Tezuka， S. Inoue， S.Fujino， H.Kato Analysis of the 
ability of cytotoxic granules and 87-1 molecule to inhibit I¥nodal 
metastases of cancer cells in breast and lung cancer patients. 7th European 
Cancer Conference， 9/1 8・21/1997
紺谷桂一、藤野昇三、 j畢井聡、手塚則明、井上修平、加藤弘文、田口修、成田達彦、平岩
望、神奈木玲児、 MUC-1遺伝子導入乳癌細胞株の腫療特異的細胞傷害Tリンパ球(CTL)
誘導能の検討、第97回日本外科学会総会、 4/9・11ハ997
紺谷桂一、藤野昇三、津井聡、手塚則明、井上修平、加藤弘文、田口修、成田達彦、平岩
望、神奈木玲児、 MUC-1 遺伝子導入乳癌細胞株の腫蕩抗原性の検討、第26回日本免疫
学会総会、 26・28/11/1996
Keiichi Kontani， Shozo Fujino， Satoru Sawai， N oriaki Tezuka， Shuhei Inoue， 
Hir01umi Kato A Breast Carcinoma Cell Line Trans1ected with MUC-1 cDNA 
Acquired the A b ility to E lic it a S peci1ic A n ti-tu m 0 r 1mm un ity in Peripheral 
Blood Mononuclear C 副Is(PBMC). 13th Asia P aci1ic Cancer Con1erence，17・
20/11/1996 
Keiichi Kontani， N oriaki Tezuka， Shuhei Inoue， Shozo Fujino， H ir01u m i Kato 
and Atsumi Mori Analysis 01 the antigenicity 01 MUC-1 mucins expressed on 
breast carcinoma cells as tumor antigens. 21th. Meeting 01 the International 
Association 10 r Breast Cancer Reseach， 7/3・5/1996 
RESEARCH RESUL TS 
Loss of the Expression or Modulation of the Carbohydrate Structures of MUC-
1 Mucin Is A M ajor Escape Mechanism of Cancer Cells from Being Recognized 
by Peripheral Tumor-Specific T Lymphocytes and Natural Killer Cells in 
Patients w ith Breast Cancer. 
ABSTRACT 
In the present study， we analyzed the antigenicity of MUC-1 mucin 
expressed on breast cancer cell lines. Ofハ7 cell lines， 6 expressing the 
mucin were readily Iyzed by PBMCs obtained from normal donors in a 51 Cr-
release assay. On the other hand， no cell Iysis was observed against a MUC-1 
deficient cell. The cell Iysis observed against the targets w ith high levels 
of MUC-1 expression was not inhibited by adding cold K562， and was 
m ediated by TCRαs/CD4 positive T Iymphocytes. The recognition of th is 
molecule was blocked by anti-M UC・1 core antibodies， or an a n ti-
carbohydrate antibody， CC49. The celllysis against the targets with the low 
expression was partially inhibited by cold K562. Also the antigenicity of 
autologous cancer cells from patients w ith breast cancer was studied. In 7 
of 26 patients， the strong Iytic activity was seen. The patients possessing 
the a ctivity showed higher re activity to anti-M UC・1core antibodies and 
CC49 of cancer cells in their tumor tissues than the patients without the 
activity， by an immunohistochemical study. However， as many as 19 patients 
showed negligible Iytic activity against their targets. Of these patients 
without the activity， 4 showed lack or a scarcity of MUC-1 expression on 
the cancer cells， and 7 demonstrated high levels of the expression but lack 
of CC49・reactivity.A MUC-1 d effic ie n t cancer ce 1lin e obtained fro m a 
patient without the Iytic activity was transfected with MUC-1 cDNA， and it 
was tested for its antigenicity. A strong activity was observed against the 
autologous transfectant. These data suggested that MUC-1 mucin has a 
crucial role in inducing a specific anti-tumor immunity as a tumor antigen 
and that the immune effector cells， T Iymphocytes and NK cells can be 
easily obtained in fresh Iy isolated PBMCs. Also i t was suggested， in 
contrast， that the unresponsiveness to cancer cells observed in many of the 
patients was mainly due to loss of MUC-1 expression or modulation of 
carbohydrate structures of the molecule. Since immunotherapy designed to 
target natural MUC-1 mucin on cancer cells was expected to have the 
lim ita tio n of its effe ct， fo r the reason， i t would be necessary to im prove a 
means to generate or enhance its antigenicity to activate the immunity. 
Keywords: MUC-1 mucin， Breast cancer， Anti-tumor immunity， T 
Iymophocyte， NK ce 1， Modulation of the antigen icity， Escape m echanism of 
cancer c e Ils
INTRODUCTION 
There have been reported many tumor antigens so far， such as 
tyrosinase， MAGE and GAGE fam ilies， MART-1， HER・2fnew，and so on， many 
of which were expressed in melanoma cells (1・6). The detailed 
investigations have clarifie d th e irnucleotide and amino acid sequences， 
physiological characteristics， tissue distributions and antigenicities. Each 
has a favor of MHC haplotypes to be presented on and acquires the ability 
to activate T Iymphocytes followed by target celllysis when it is presented 
on the appropriate MHC molecule. On the other hand， MUC-1 mucin has been 
demonstrated to be recognized by T Iymphocytes in a MHC unrestricted 
manner (7). The mechanism of the recongnition by T Iymphocytes， and cell 
surface molecules and Iymphokines involved in the recognition s til remain 
unclear. It is likely， however， that this mucin is recognized by CTLs not 
according to the already-known interaction of antigenic peptides presented 
on MHC molecules and TCR. The unique structure of the molecule should be 
taken in to account to explain the unusual manner. A 10 t of tandem repeats， 
approximately twenty to a hundred， which are encoded in the core protein 
and contain conserved twenty amino acid sequences (8・12)， may acquire the 
adequate affinity to antigen binding regions of TCR. It results in the 
activation of CTL， despite the antigenic peptide presented not in the context 
of MHC molecules. On the other hand， the exposure of the epitopes in the 
tandem repeat domain was greatly affected by carbohydrate structures 
bound on the core protein (13). The mucin is also known to be expressed 
abundantly on cancer cells such as breast， pancreatic and ovarian cancer 
(14-16). Recent studies demonstr.ated that the mucin was abberantly 
expressed on various cancer cells， i.e.， inlung cancer， gastric cancer and 
colon cancers， etc. (17-19). Because of the abundant expression， MUC-1 
mucin has been widely used as a tumor marker， CA15-3， to predict the 
cancer progression or to evaluate the effe ct of an anti-cancer treatm ent to 
perform. It is expressed on normal epithelial cells of the ducts as well. 
However， glycosylations of th is molecule on normal cells was reported to be 
different from those on cancer cells (20). Long and complexly branched 
carbohydrates on normal cells ordinarily mask MUC-1 core proteins and 
surface m olecules on the ce Is， suggesting th a t antigen ic determ inants 
capable 01 activating immune response are physic剖Iyseggregated 1rom the 
immune system. There10re， to determine what structure 01 the mucin has 
the antigenicity recognizable by the host immune system， what population 
01 e11ector cells are responsible 10 r the recognition， and whether it is 
possible to manupulate the antigenicity and the e11ector 1unction， 10r the 
purpose 01 immunotherapy against the cancer. 
We investigated the relationship between expression levels and 
patterns 01 MUC-1 mucin in cancer cells and its antigenicity as a tumor 
antigen， using breast cancer ce 1lin es showing d i11e re n t expressions 01 the 
mucin and breast cancer cells obtained 1rom cancer patients. From the MUC-
1 phenotype 01 the cancer cells， major causes 10r resistance 01 the cancer 
ce Is to tum or ce 1Iys is by P8MCs were concluded. Three dim entional 
structures 01 carbohydrate side chains as well as tandem repeat domains 
containing the antigenic determ inants as reported by Jerome et al. (21) on 
the molecule were im portant in e licitin 9 anti-tu m or immune response in 
hosts. In 1reshly isolated P8MC， two e11ector populations， CD3/CD4 positive 
T Iymphocytes and NK cells， were involved in the MUC-1 speci1ic 
cytotoxicity. However， our conlusions were not supportive to targeting 
natural MUC-1 molecule as a tumor antigen 10r anti-cancer immunotherapy. 
MATERIALS AND METHODS 
Monoclonal Antibodie~. DF3， 115D8， 872.3 and CC49 were provided 
1rom Toray-Fuji 8ionics -Inc. (Tokyo， Japan). SM3 was purchased 1rom 
Cymbus 8ioscience Ltd. (Southampton， UK)， and TKH・6was 1rom Otsuka 
Pharmaceutical Co. (Tokushima， Japan). Antigenic determ inants w ith which 
these antibodies react 01 MUC-1 mucin are summarized in table 1. SNH3， 
which is reactive w ith sialyl・Lex，was kindly given 1rom Dr. S en-itiroh 
Hakomori， 8iomembrane Institute (Seattle， WA). J¥Anti-human CD4 and CD8 
monoclonal antibodies were purchased 1rom Seikagaku corp. (Tokyo， Japan)， 
and anti-human TCRab monoclonal antibody was 1rom Cosmo 8io. Co.， Ltd. 
(Tokyo， Japan). 
Table 1 Monoclonal antibodies or a lectin used and their antigenic 
determinants on I¥征JC-lmucin 
Antibodies used Antigenic structures detected with antibodies 
Anti-MUC-l Core 
DF3 
115D8 
SM3 
Anti-Carbohydrate 
TKH・6
B72.3 
PNA 
∞49 
?，?? ???
??????? ??
?
??
GalNAc-O-Ser/Thr (Tn) 
NeuAcα2，6GalNAc-O-Ser/Thr (sialyl・Tn)
Gals 1 ，3 GalNAc-O-Ser /Thr (TF) 
Galsl，3(NeuAcα2，6)GalNAc-O・Ser/Thr
Reaaents: Dispase was purchased from Godo Shusei Co. Ltd. (Tokyo， 
Japan)， Ficoll-Conray Lymphosepal from Immuno・Biological Laboratories 
(Gunma， Japan) and Na251 Cr04 from DuPont NEN (Boston， MA). PNA reactive 
w ith TF， m ucin-associated carbohydrate structu res was purchased fro m 
Seikagaku corp. (Tokyo， Japan). Sialydase and G eneticin (G418) were fro m 
GIBCO BRL (Tokyo， Japan). 
C el lin es: ZR75-1， T47D， BT・20，SK・BR3，MDA-MB231 and K562 were 
purchased from American Type Culture Collection (Rockvill， MD). MCF-7 was 
kindly given from Dr. Shunzo Kobayashi， Second Department of Surgery， 
Nagoya City University (Nagoya， Japan). NZK-K1 was established from a main 
tumor of a 45・year-oldfem ale breast cancer patient， by 9 raftin 9 the tum or 
specimens subcutaneously ih female Scid mice which were purchased from 
Charles River Inc. (Hino， Japan). 
Preoaration of breast cancer cells: Breast cancer cells were freshly 
isolated from main breast tumors of the patients at the tim e of operations. 
Resected tum or samples were minced and incubated in RPMI supplemented 
with dispase at the concentration of 10，000 PU/ml at 370C for 60 min to 
single ce 1suspensions. The suspensions were layered on the top of step 
gradients， from the bottom comprising 100% and 75% Iymphosepal and 
centrifuged at 400 x 9 fo r 30min. Tumor cells were collected from the 
interface of the sample and 75% Iymphosepal layer and resuspended in RPMI 
containing 2% FCS. 
Preoaration of Perioheral Blood Mononuclear Cells (PBMC):_Heparinized 
periphral blood samples obtained from the patients were diluted in the same 
volume of PBS， layered on Iymphosepal and centrifuged at 400 x 9 at room 
tem perature fo r 30 min. PBMCs were collected from the interface of the 
sample and Iymphosepal layer and resuspended in RPMI containing 2% FCS. 
lmmunohistochemical Studv! Tumor specimens obtained from the 
main breast tumors were either fixed in 10 % formalin and embedded in 
paraffin or frozen in OCT compound in liquid nitrogen. Paraffin-embedded 
secrtions were incubated w ith monoclonal antibodies diluted to th e ir
appropriate concentrations in PBS at room temperature for 2 hours 
following pre-incubation in 0.2% hydrogen peroxide-containning methanol to 
block non-specific binding sites on them. A fte r three washes in PBS， they 
were incubated w ith peroxidase-conjugated anti-m ouse IgG diluted a t 
1/200 in PBS at room temparature for 30 min. They were washed in PBS 
three tim es and incubated in 5 mM Tris-H C I containing diam inobentidine to 
visualize for 10 min. After washing in distilled water， nuclear compartment 
of cancer cells were stained in hematoxylin solution. They were dehydrated 
in 100% ethanol and mounted in 50% glycerin. Frozen sections were fixed in 
50% chloroform solution and reacted to be stained according to an indirect 
peroxidase-staining technique as described above. 
Flow Cvtom etric Analvsis! Breast cancer cell lines were suspended in 
PBS and incubated w ith antトMU C-1 monoclonal antibodies d iluted on ice fo r 
30 min. After three washes in cold PBS， the cells were incubated with 
FITC・conjugatedanti-m ouse IgG diluted at 1/1000 on ice fo r 30 min. Flow 
cytom etric analyses were perfomed using a FACScan flow cytom eter 
(Betton Dickinson， San Jose， CA) following three washes in cold PBS. 
C vtotoxicitv Assav. Breast cancer cell lines or cancer cells obtained 
from cancer patients were incubated with Na251Cr04 at 370C for 60 min. 
104 cells. radio-Iabeled were transfered to a 96 well U-bottom culture 
plate containing 5 x 105 PBMCs prepared in 200m I RPMI supplemented w ith 
10% FCS and 5 x 1 0・5M 2・Mercaptoethonolfollowing three washes in 
medium. They were incubated at 370C. 18 hour incubation tim e was employed 
to measure the cytotoxicity mediated by cytokines such as TNFa or IFNg as 
w e 1 as by cytotoxic granules， as previously reported (1， 22・23). To 
abrogate NK-mediated cytotoxicity， 2 x 105 K562 were added to each w e 1 
containing effector and radio-Iabeled target cells. To inhibit the recognition 
of antigenic structures by effector cells， target cells were pre・incubated
with anti-MUC・1monoclonal antibodies a t 370C fo r 45 m in in p rio r to co・
cultu re w ith effector cells. To investigate what population of effector 
cells was responsible for the tumor cell Iysis， PBMCs were treated with 
anti-TCRαs， CD4 or CD8 antibodies at 370C fo r 45 m in followed by co・
incubation w ith radio・labeledtarget cells. After 18 hours incubation of 
target cells and PBMCs， the supernatant was collected 1rom each well and 
counted 10r the release 01 51Cr 1rom the Iyzed target cells， using LKB-
Wallac Minigamma 1275 (Wallac Oy.， Finland). The percentage 01 chromium 
release was determined by the 10rm ula: 
Experim ental release ・Spontaneousrelease 
%Iysis = x 100 
Maximal release ・ Spontaneousrelease 
Tans1ection 01 a Breast Cancer C el Line w ith MUC-1 cONA. MUC-1 
cONA expression vector， pOKOF.muc1 (30) was kindly given by Or. O. J. Finn 
(U niversity 01 Pittsburgh， Pittsburgh， PA). Trans1ection 01 a MUC-1 
de11icient cell line， NZK-K1 with the cONA was per10rmed， using the 
electroporation technique as described previously (24). 
RESULTS 
Phenotvoic Analvsis 01 Breast Cancer Cell Lines bv FACS. Seven breast 
cancer cell Iines were stained w ith monoclonal antibodies directed to the 
MUC-1 core， the associated carbohydrate or MHC molecules as described in 
'M aterials and Methods'. They were tested 10 r th e irphenotypes on the ce 1
sur1ace by FACS (Fig. 1).' NZK-K1 showed lack 01 MUC-1 mucin and high 
levels 01 both class 1 and 1 expressions. MOA-MB231 and SK-BR3 
demonstrated low expressions 01 the tandem repeat domain， detected w ith 
OF3 and 11508， and no expression 01 the m ucin-associated carbohyrates. 
Although high expressions 01 the tandem repeat， detected w ith OF3 and 
11508， was seen in ZR75-1， BT・20and T470， a strong reactivity to SM3 
was shown in BT・20 and T470， but not in ZR75-1. 01 carbohydrate 
structures， the determinants detected with CC49 were strongly expressed 
in ZR75-1 and T470， and weakly but apparently expressed in BT・20. Other 
oligosaccahride stru ctu res， detected w ith TKH・6or B72.3， were not 10und in 
these cells. MCF-7 showed interm ediate levels 01 tandem repeat and a 
scarcity 01 the cabohydrate expression. 
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Figure 1. Flow cytom etric analysis 01 MUC-1 expressions in breast cancer 
ce 1lines. Monoclonal antibodies directed to the MUC-1 core， the associated 
carbohydrate or MHC molecules listed in table 1 were used 10 r the assay. 
Seven breast cancer cell lines were stained w ith the antibodies at the 
appropriate concentration o!，! ice 10 r 30 min. A fte r three washes in PBS， they 
were incubated w ith FITC-conjugated anti-m ouse IgG antibody on ice 10 r 30 
min. Then， they were tested 10 r th e irphenotypes by FACS. 
Cvtotoxic a ctivitv 01 PBMCs aaainst alloaeneic breast cancer ce 1
lin豆主ム PBMCsobtained 1rom normal donors were incubated w ith isotope-
labeled breast cancer cell lines at e11ectorjtarget ratio 01 50:1. A1ter 18 
hour incubation， the supernatant was collected and measured 10 r the release 
01 51Cr1rom the Iyzed targets. Whereas the strong Iytic activity against all 
the target cells expressing MUC-1 mucin was 10und， no activity was against 
a MUC-1 de11icient cell， NZK-K1 (Fig. 2A). The percentage 01 tumor cell 
Iysis observed did not correlate w ith the mucin expression level on the 
cells. To investigate whether NK cells in the PBMCs were involved in the 
cells Iysis observed， cold K562 which is known to be sensitive to NK-
mediated cytotoxicity was added to each w e 1 containing PBMCs and labeled 
targets. The ce 1 Iysis against ZR75-1 w ith high levels 01 the m ucin 
expression was not inhibited by K562. And that against MCF・7with the 
lower expression was in h ibitedハtoa third 01 the activity without adding 
K562 (Fig. 2B). The same resu Its were obtained against T47D and SK-BR3 
(data not shown). Whereas added K562 did not a11ect the cell Iysis against 
T47D， it did that against SK-BR3. Since the e11ector cells showed 
approximately 20 % Iytic activity against K562， NKcells were suggested to 
be present in the PBMC prepared (Fig. 2B). 
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Figure 2. Cytotoxic activity 01 PBMCs against allogeneic breast cancer cell 
lines. 1 x 104 breast cancer ce Ils labeled w ith 51 Cr were incubated w ith 5 x 
105 PBMCs obtained 1ro m norm al donors in each w e 1 10 r 18 hours. The 
supernatant was collected 1rom the w e 1 and counted 10 r the release 0151 Cr 
1rom the Iyzed target cells. (A). 2 x 105 non-Iabeled K562 were added to a 
w e 1 containing PBMCs and labeled MCF・7or T47D， to abrogate NK-mediated 
cytotoxicity. The percentage cell Iysis was calculated as described above 
(B). They were per10rmed in triplicate. 
inhibitorv e11ect 01 anti-MUC・1antibodies on the cvtotoxicitv aaainst 
MUC-1 exoressina taraet cells! The three ce 1lin es w ith high levels 01 MUC-
1 expression， ZR75-1， BT・20and T47D were pre-treated w ith anti-M UC・1，
or anti-m ucin-associated carbohydrate antibodies 10110wed by co・
incubation w ith PBMCs. 01 the three cells， the cytotoxicity against BT -20 
and T47D， both 01 which showed the strong reactivity to SM3， was inhibited 
by th is antibody (Fig. 3A). In contrast， th a t against ZR75・1with a scarcity 
01 the reactivity was not inhibited by it. The cytotoxicity against all 01 
them was vigorously inhibited by CC49， and not by antibodies to MHC 
molecules (Fig. 3A). Against the targets w ith lower levels 01 MUC-1 
expression， MCF-7， SK-MR3 or MBA-MD231， the cell Iysis was partially 
inhibited by antibodies to the tandem repeat and the carbohydrate (data not 
10wn). To study what population 01 effector cells was responsible 10 r the 
uc・1speci1ic cytotoxicity obtained， PMBCs were treated w ith anti-TCRab， 
04 or CD8 monoclonal antibody in p rio r to co・incubationw ith radio-Iabeled 
rgets in the cytotoxicity assay. Anti-TCRab and CD4 antibodies were 
10wn to in h ib it the ce 1Iysis against ZR75-1 by PBMCs (Fig. 3B). Anti-C D8 
1tibody did not a 11e ct the cytotoxicity. The Iy tic a ctivity against T47D was 
hibited by the treatm ent 01 anti-TCRab and CD4 antibodies as w e 1 (data 
)t shown). 
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antibodles added antlbodles diluted at 
igure 3. Inhibitory e11ect 01 anti-MUC・1monoclonal antibodies on the 
ytotoxicity against breast cancer cell lines with high levels 01 MUC-1 
xpression. ZR75-1， BT・20and T47D， a 101 which showed high expressions 
f the mucin， were pretreated with anti-MUC・1antibodies or anti-MHC 
ntibodies at 370C 10r 45 min in prior to co-incubation with PBMCs. 
lmmunohistochemical studies 01 breast tumors 1rom the patients. 
wenty-six 1emale patients ranging in age 1rom 32 to 77 and in clin ical 
tage 1rom 1 to 3 were studied. C linical 1eatures 01 the patients were 
ummarized in Table 2. Para11in-embedded or 1rozen sections 01 the tumor 
Ssues were stained w ith anti-M UC・1 antibodies， using an in d ire ct 
~i1 munoperoxidase technique. The cancer cells were stained intensely and 
if1usely in the cytoplasm in the tumor tissues in some cases (data not 
hown). Cancer cells 10rming glandular structures were stained in their 
!Pical borders in some cases (data not shown). The percentage 01 positive 
lels were calculated by the number 01 positively stained cells out 01 1ive 
lundred cancer ce Is counted. Mean percentages 01 pos itive ce Is 10 r each 
ntibody-reactivity were shown in Fig. 4. The expression 01 the tandem 
r~peat was particularly higher than that 01 the carbohydrate in the cancer 
lels (Fig. 4). Ninety-two percent 01 breast cancer patients studied were 
positive fo r the mucin expression in the tum ors (data not shown). 
studied patients breast of features Table20inical cancer 
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Figure 4. Mean percentages of cancer cells positively stained w ith an ti・
MUC-1 antibodies in the breast tumors. The percentage of cancer cells 
positive for the antibody were calculated by the number of positive cells 
out of 500 cancer cells counted. Mean percentages of positive cancer cells 
fo r each antibody were shown. 
Cvtotoxic a ctivitv of PBMCs from oatients w ith breast cancer aaainst 
autoloaous cancer cells~ Freshly isolated PBMCs from the patients were co・
incubated with 51Cr-labeled autologous cancer cells for 18 hours. The 
percentage of tumor cell Iysis in each case was plotted (Fig. 5). The 
percentage of more than 6".3% was statistically significant (p<0.05). Seven 
(27%) out of tw e n ty-s ix cases showed positive fo r the cytotoxic a ctivity. 
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Figure 5. Cytotoxic activity of PBMCs from patients w ith breast cancer 
against autologous cancer cells. Breast cancer cells prepared as described 
in 'M aterial and Methods' from the patients were incubated w ith fresh Iy 
isolated PBMCs following radio-Iabeling for 18 hours. The percentage of 
tumor cell Iysis in each case was plotted. 6.3 % Iytic activity was 
statistically significant (p< 0.05). 
Correlation between MUC-1 expression in cancer cells and their 
s usceptibilitv to tumor cell Ivsis bv PBMCs: The patients studied were 
divided into two groups， the positive and negative cases for the anti-tum or 
cytotoxicity. Thereactivity oftumorcells to each anti-MUC・1antibody was 
compared between the two groups， by the immunohistochemical study 
(Fig.6). The percentage of cancer cells positive fo r DF3， 115D8 and CC49 
was significantly higher in the positive cases comparable with that in the 
negative cases. A 1 of the 7 positive cases showed a strong MUC-1 
expression in their tumors (data not shown). Of the 19 negative cases， 
however， only 2 cases showed lack of the expression， and 2 were the low 
expression cases (% positive cells < 40 %). Although the remaining 15 
negative cases showed a strong expression of MUC-1 tandem repeat， 7 of 
them had lack or a scarcity of C C49・reactivityin th e irtu m ors (data not 
shown). 
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Figure 6. Relationship between MUC-1 expression in cancer cells and its 
ability to elicit anti-tumor immunity. The patients studied were divided 
into two groups， positive and negative cases， according to the result of theJ¥ 
autologous cytotoxicity assay performed. Mean percentages of cancer cells 
positive for the reactivity to each anti-MUC・1antibody was compared 
between the two groups. 
MUC-1 Expression and Antiaenicitv of A Transduced Breast Cancer Cell 
Line. A hundred and nineteen MUC-1 cONA transduced clones were obtained， 
and they were screened for their MUC-1 expression by FACS. As the result， 
six clones showing the strong expression were obtained. By FACS， one of the 
six clones showed obvious levels of MUC-1 core expression (Fig. 7). 
Treatm ent of th is transfectant w ith sialydase increased the a 1levels of 
the core expression and of C C49・reactivityon it (Fig.7). 
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Figure 7. Phenotypic analysis of MUC-1 transfectants by FACS. A MUC-1 
defficient parent cell line， NZK-K1， a MUC-1 transfectant， NZK-muc and a 
sialydase・treated NZK-muc were stained w ith anti-M UC・1 antibodies. 
Phenotypes of these ce 1lines were studied as described in 1M aterials and 
Methodsl • 
To test the antigenicity of the MUC-1 transfectant， radio・labeledNZK-
K1， NZK・muc or sialydase-trreated NZK-muc were co・incubated w ith 
autologous PBMCs at E/T ratio of 50 for 18 hours. After the incubation， the 
supernatant was colected and measured fo r the amount of isotopes released 
from the Iyzed targets. Although the parent cells were scarcely killed by 
the PBMCs， the transfectants and T470 were readily Iyzed (Fig. 8). 
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Figure 8. Analysis 01 the antigenicity 01 MUC-1 trans1ectants. Radio-Iabeled 
targets， NZK-K1， NZK・mucand sialydase・treatedNZK・mucwere incubated 
w ith autologous PBMCs 10 r 18 hours. The amount 01 isotope released 1rom 
Iyzed targets were calculated as described in 'M aterials and Methods'. 
DISCUSSION 
In this study， breast cancer celllines with MUC-1 mucin expression on 
the sur1ace were demonstrated to be readily killed by PBMCs 1rom normal 
donors in the allogeneic cytotoxicity assay (Fig. 2A). On the other hand， NZK-
K1 lacking the expression was not Iyzed. I t suggested th a t MUC-1 m ucin 
expressed on the cancer cells were speci1ically recognized and Iyzed by 
PBMCs 1rom normal donors. To com1irm that it was a speci1ic anti-MUC・1
immune response， inhibitory e11ects 01 anti-MUC・1 antibodies on the 
cytotoxicity against I¥the cancer cells was tested. The cytotoxicity observed 
against three targets w ith the high expression， T470， ZR75-1 and BT -20 
was vigorously inhibited byanti-MUC・1antibodies， whereas the in h ibito ry 
e11ect against targets w ith lower expressions was partial (Fig. 3A). In 
particu lar， against BT・20 and T470， both 01 which had SM3・reactive
determ inants， POTRP w ith in the tandem repeat domain， the cytotoxicity was 
inhibited by this antibody. However， that against ZR75-1 with a scarcity 01 
the SM3 reactivity was not inhibited by it. Against the all three targets， it
was greatly inhibited by CC49 reactive w ith mucin core 2 trisaccharide 
stru ctu res， Galb1 ，3 (NeuAca2，6)GaINAc・o-Ser/Thr.These data suggested th a t 
not only the tandem repeat domain containing the antigenic epitope as 
previously reported (11) but also three dimensional structures including the 
carbohydrate side chains may determine the susceptibility 01 the cancer 
cells to MUC-1 speci1ic anti-tumor immunity. 
The cytotoxicity observed agaist ZR75-1 and T47D was inhibited by 
antibodies to TCRab and CD4 (Fig. 38) and not in h ib ited by adding cold K562 
(Fig. 28). It was suggested that e11ector cells responsible 10r the tumor cell 
Iysis were TCRab/CD4 positive T Iymphocytes， and that these cells 
speci1ically recognized and Iyzed MUC-1 expressing cells without a MHC 
restriction. The cell population characterized as large granular Iymphocytes 
which can k il K562， like NK cells or NKT cells， was not involved in the 
cytotoxicity against these cells with the high expression. It was unlikely 
that some populations 01 T Iymphocytes in 1reshly isolated P8MCs 1rom 
normal donors could recognize J¥the tumor antigen without prior priming in 
vitro or in vivo. I t m ight be possible， however， th a t naive T Iymphocytes 
already encountered the mucin， which was shed 1rom glandular epithelial 
cells， or which was processed and presented by phagocytes 101l0wing 
apoptotic death 01 the epithelial cells in normal individuals. In 1act， there 
has been several reports th a t less than 10 % 01 normal individuals as w e 1 
as 10 % to 60 % 01 cancer patients showed the existance 01 soluble MUC-1 
m ucin in th e ir sera (25・28). I t indicates th a t some populations 01 T 
Iymphocytes have already been primed with MUC-1 mucin and can be re-. 
activated im m ediately in response to cancer ce Is expressing the mucin. 
Also， there has been a reported data 01 approxim ately 15 % 01 cancer 
patients w ith antisera to MUC-1 mucin (29). I t is possible th at normal 
individuals as w e 1 as cancer patients may have some already-prim ed T 
Iymphocytes speci1ic 10 r MUC-1 mucin in th e irP8MCs. Other populations 01 
e11ector cells responsible 10r the cell Iysis was NK cells， because the 
cytotoxicity observed against MCF-7 expressing lower level 01 the mucin 
was inhibited by adding cold K562 in the cold target inhibition assay (Fig. 
28). It was an unexpected result that the recognition 01 target cells with 
the low expression by the e11ector cells， one population 01 which was a NK 
cell， was blocked by anti-MUC・1antibodies (data not shown). Recently， 
Adachi et al. (30) reported that the increase 01 MUC-1 core expressions by 
blocking GalNAc trans1erase activity resulted in inducing M UC・1・speci1ic
cytotoxicity mediate by NK and LAK cells. Taken together， itwas indicated 
that both 01 the two populations， CD3/CD4 positive T Iymphocytes and NK 
cells were involved in the speci1ic recognition and the cell Iysis 01 cancer 
cells expressing MUC-1 mucin. 
We underwent analysis 01 the antigenicity 01 MUC-1 mucin expressed 
on breast cancer cells obtained 1rom patients w ith breast cancer. In the 
autologous cytotoxicity assay， an apparent cytotoxic activity 01 P8MCs 1rom 
the patients was observed against autologous cancer cells expressing high 
levels of MUC-1 tandem repeats， detected w ith either OF3 or 11508， or of 
CC49・reactivestructures. The result obtained was compatible with that in 
the allogeneic cytotoxicity assay， interm s th a t he a b ility to e lic it a strong 
an ti-tu m 0 r imm u n ity was affected by not only tandem repeat expression but 
also carbohydrate side chains bound on the core protein. Taken together， we 
comfirm ed th at the expression of the tandem repeat as w e 1 as core 2 
trisaccharide strucures were im potant in the autologous response inducing 
a strong an ti-tu m or im m unity. Considering the unique stru ctu re and 
characteristics described above， we are thinking of some possibilites to 
explain the results obtained. Immune effector cells-involved in the tumor 
cell Iysis may recognize three dimensional structures formed by the core 
peptides and the carbohydrates， reffered to as a m olecular m im icry， instead 
of antigenic peptides in the context of MHC molecules. Or the carbohydrate 
structures detected w ith CC49 bound on the core protein may cause the 
conform ational change of the whole m ucin， leading to the increase of 
exposure of the epitope in the tandem repeat. 
Jerome et al. reported that MUC-1 expressing target cells were Iyzed 
by MUC-1 specific CTL established after stimulation of PBLs with EBV-
transformed B cells transfected with MUC-1 cONA， whereas not killed were 
MUC-1 defficient cells (31). In addition， the mucin expressing target cells 
which were pretreated w ith glycosylation in h ib itors to increase the tandem 
repeat expression were reported to be Iyzed more efficie n tly by the CTL. The 
tumor cell Iysis shown could be blocked by adding anti-MUC・1monoclonal 
antibodies to the tandem repeat such as SM3 and HMFG-1 and 2 (32・33).The 
data suggested that there m ight be antigenic epitopes recognized by CTL， 
POTRP in the repeat domain was the most likely， on the MUC-1 core and th at 
they could induce a cell-madiated immune response to tumor cells 
expressing the mucin. The epitope responsible fo r the induction was 
reported to be ordinarily masked on normal mammary epithelial cells or 
some breast cancer cells， with sialic acids or fucoses which terminates 
carbohydrate side chains (29). AII of the cancer patients with Iytic activity 
in the autologous cytotoxicity assay demonstrated a strong MUC-1 
expression in the cancer cells (data not shown). On the other hand， of 19 
patients without the activity， only 2 were negative for MUC-1 expression in 
their tumors and 2 showed a scarcity of the expression (% positive cancer 
cells < 40%). Although the remaining 15 patients showed strong MUC-1 core 
expressions in the tum ors， 7 of them were negative fo r C C49・reactivity
(data not shown). These data suggested that at least a strong expression of 
MUC-1 mucin on cancer cells was required for the specific turi10r cell Iysis 
by PBMCs， but it was not sufficient. Modulation of carbohydrate structures 
as well as loss of expression of the molecule could be an escape mechanism 
of cancer c 剖恰 from being recognized by immune effector cells. The 
unresponsiveness of PBMCs to the autologous cancer cells observed was not 
caused by dysfunction of the effector cells in the patients， because the 
cytotoxic activity of PBMCs from a cancer patient showing no autologous 
tumor cell Iysis was observed against the autologous MUC-1 transfectant in 
the cytotoxicity assay (Fig.8). Treatm ent of the transfectant w ith sialydase 
to modify the carbohydrate structure of the mucin led to the restoration of 
anti-tumor immunity by the PBMCs. 
MUC-1 mucin has been thought to be im portant not only as tum or 
markers in diagnosis and in evaluation of the effect of anti-cancer 
treatm ent to carry out but tum or antigens th at can be p ilo ried fo r 
immunotherapy against cancer. We had a supportive data that 92% of 
patients w ith breast cancer studied were shown to be positive fo r MUC-1 
mucin in their tumors byan immunohistochemical study (data not shown). 
Since the mucin can elicit an anti-tumor immunity in MHC unrestricted 
manner， itis easy to obtain or activate tum or-specific T Iymphocytes or NK 
cells from the patients' PBMCs， using allogeneic cancer cell lines expressing 
a favorable MUC-1 mucin ex vivo as stim ulators， for the purpose of adoptive 
immunotherapy. Or transfection of glucosyltransferase cDNA or its 
antisense nucleotide as well as MUC-1 mucin cDNA into cancer cells to 
modify the antigenicity in vivo can be employed for the treatment， so that 
the transduced cells can be efficiently recognized by MUC-1 specific CTL. 
Taking into account of the escape mechanism of the cancer cells observed， 
however， itshould be concluded that targetting the natural MUC-1 mucin 
expressed on cancer cells as a tumor antigen is not expected to obtain 
successful effects for anti-cancer immunotherapy. Further investigation is 
necessary to generate or increase the antigenicity of this molecule. 
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